Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
- Mechanism
- Curator reviewed
R343 is a syk kinase inhibitor. Syk kinase is a protein tyrosine kinase that plays a pivotal role in high affinity IgE receptor signaling in mast cells. Syk kinase inhibitors bind to syk in mast cells interrupting the signal from the Immunoglobulin E (IgE receptor), thus preventing cellular activation and subsequent chemical mediator release, and potentially blocking an allergic response in allergic asthma. Allergic asthma is a chronic inflammatory disorder of the airways whereby persistent inflammation of the airway passages results in airway obstruction. In some patients, allergens, such as pollen, trigger the production of immunoglobulin E antibodies (IgE antibodies) which then bind to mast cells and cause an intracellular signal that results in the release of various chemical mediators. [Rigel Pharmaceuticals Press Release]
- Primary indication
- Investigated for use/treatment in allergic reaction and asthma.Curator reviewed
- Formula / weight
- C21H17F3N6O4 · 474.4 g/mol (avg)
- Also known as
- 2- {3- [4-(2,2-Difluoro-3 -oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-ylamino)5-fluoro-pyrimidin-2-ylamino]phenoxy}N-methyl-acetamide
- Code names
- R-940343
Resolves to
MOXXQFNQDDSJHT-UHFFFAOYSA-NSMILESCNC(=O)COC1=CC=CC(NC2=NC=C(F)C(NC3=CC=C4OC(F)(F)C(=O)NC4=C3)=N2)=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with R343, and which of those have an active Phase 3 trial?